Full Text
Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam

Abstract

Authors

T.T.H. Tran T.T.T. Nguyen

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×